Both low calorie diets, particularly those incorporating satiating meal replacement products, and incretin mimetics (GLP1RA, GLP1RA/GIPRA combinations) can facilitate important levels of weight loss. We will compare and contrast these approaches to weight change in terms of acceptability and adverse effects, evidence for effects on weight and cardiometabolic endpoints, and need for support and follow-up. We will discuss trials that we are conducting that are examining effects of low calorie meal replacement product-based diets in combination with supervised exercise and food-based low calorie dietary approaches. We will stimulate discussion of a personalized medicine approach to selecting the right approach for an individual patient.
Kaberi Dasgupta is a Physician, Scientist, and Professor of Medicine at McGill University and the McGill University Health Centre, and McGill Director of General Internal Medicine. Her research focus is prevention, remission, and self-management support in diabetes and cardiometabolic disease. Her research is funded by the CIHR, Heart & Stroke Foundation, Lawson Foundation, and Diabetes Canada. She has published 168 papers to date. Her research has received a high level of media coverage because of its direct relevance to patients, practitioners, and policy makers. She co-authors Diabetes Canada’s clinical practice guidelines on remission, physical activity, and type 2 diabetes pharmacotherapy.